LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article: Unusual Observations of Neurological Cases in Patients with Simultaneous Corona Infection - (A Hospital-Based Study).

    Chakraborty, Debashis / Haldar, Amit

    The Journal of the Association of Physicians of India

    2021  Volume 69, Issue 5, Page(s) 22–24

    MeSH term(s) Hospitals ; Humans
    Language English
    Publishing date 2021-06-29
    Publishing country India
    Document type Journal Article
    ZDB-ID 800766-4
    ISSN 0004-5772
    ISSN 0004-5772
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Jaundice, fever and anaemia: when to avoid the cold.

    Al-Shakhshir, Sarah / Bannaga, Ayman / Kaddam, Israa / Cain, Owen / Haldar, Debashis / Armstrong, Matthew James

    Frontline gastroenterology

    2022  Volume 14, Issue 3, Page(s) 267–268

    Language English
    Publishing date 2022-05-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2521857-8
    ISSN 2041-4137
    ISSN 2041-4137
    DOI 10.1136/flgastro-2022-102147
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Deciphering the biology of IgG4-related disease: specific antigens and disease?

    Haldar, Debashis / Hirschfield, Gideon M

    Gut

    2017  Volume 67, Issue 4, Page(s) 602–605

    MeSH term(s) Antigens ; Autoimmune Diseases ; Autoimmunity ; Humans ; Immunoglobulin G
    Chemical Substances Antigens ; Immunoglobulin G
    Language English
    Publishing date 2017-11-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2017-314861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Overlap syndrome: A real syndrome?

    Haldar, Debashis / Hirschfield, Gideon M

    Clinical liver disease

    2014  Volume 3, Issue 3, Page(s) 43–47

    Language English
    Publishing date 2014-04-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2657644-2
    ISSN 2046-2484
    ISSN 2046-2484
    DOI 10.1002/cld.317
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Mesenchymal stromal cells and liver fibrosis: a complicated relationship.

    Haldar, Debashis / Henderson, Neil C / Hirschfield, Gideon / Newsome, Philip N

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

    2016  Volume 30, Issue 12, Page(s) 3905–3928

    Abstract: ... in the context of liver injury and fibrosis.-Haldar, D., Henderson, N. C., Hirschfield, G., Newsome, P. N ...

    Abstract Mesenchymal stromal cell (MSC) therapy demands the attention of clinicians and scientists because of its potential in clinical fields that are bereft of medical options, but also because of the controversies that underlie its mode of action. MSCs are potent immune modulators, yet their biologic activity may not be innate, requiring licensing by their microenvironment. This property has prompted researchers to explore unique ways in which MSCs may be able to exert distinct biologic effects in different pathologic settings. More than 400 clinical trials have investigated the therapeutic capacity of MSCs in different pathologies, including liver disease. Along with their anti-inflammatory action, there are data to suggest that MSCs may exert direct antifibrotic effects, although enthusiasm for their use in patients has been tempered by concerns of a possible profibrotic role of endogenous MSCs in response to injury. There is a significant need for antifibrotic therapy to combat the increasing burden of patients with cirrhosis, and a concerted effort is required to determine the mechanisms by which MSCs modulate the liver's response to injury, both endogenously and after adoptive transfer. This review critically appraises the preclinical published data with regard to the capacity of MSCs to influence fibrotic response to liver injury and will explore the potential mechanisms that underpin the reported beneficial effects of MSC therapy in the context of liver injury and fibrosis.-Haldar, D., Henderson, N. C., Hirschfield, G., Newsome, P. N. Mesenchymal stromal cells and liver fibrosis: a complicated relationship.
    MeSH term(s) Animals ; Cell- and Tissue-Based Therapy/methods ; Fibrosis/therapy ; Hepatic Stellate Cells/cytology ; Humans ; Liver Cirrhosis/pathology ; Liver Cirrhosis/therapy ; Mesenchymal Stem Cell Transplantation/methods ; Mesenchymal Stem Cells/metabolism ; Mesenchymal Stem Cells/pathology
    Language English
    Publishing date 2016-09-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 639186-2
    ISSN 1530-6860 ; 0892-6638
    ISSN (online) 1530-6860
    ISSN 0892-6638
    DOI 10.1096/fj.201600433R
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: An overview of the diagnosis and management of immunoglobulin G4-related disease.

    Haldar, Debashis / Cockwell, Paul / Richter, Alex G / Roberts, Keith J / Hirschfield, Gideon M

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

    2016  Volume 188, Issue 13, Page(s) 953–961

    MeSH term(s) Autoimmune Diseases/diagnosis ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/immunology ; Azathioprine/therapeutic use ; Disease Management ; Glucocorticoids/therapeutic use ; Humans ; Immunoglobulin G/immunology ; Immunologic Factors/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Induction Chemotherapy ; Maintenance Chemotherapy ; Rituximab/therapeutic use
    Chemical Substances Glucocorticoids ; Immunoglobulin G ; Immunologic Factors ; Immunosuppressive Agents ; Rituximab (4F4X42SYQ6) ; Azathioprine (MRK240IY2L)
    Language English
    Publishing date 2016-06-20
    Publishing country Canada
    Document type Journal Article ; Review
    ZDB-ID 215506-0
    ISSN 1488-2329 ; 0008-4409 ; 0820-3946
    ISSN (online) 1488-2329
    ISSN 0008-4409 ; 0820-3946
    DOI 10.1503/cmaj.151402
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.

    Haldar, Debashis / Janmohamed, Ashnila / Plant, Tim / Davidson, Matthew / Norman, Hannah / Russell, Emily / Serevina, Olivia / Chung, Kenneth / Qamar, Kashif / Gunson, Bridget / Hansen, Bettina / Richter, Alex / Trivedi, Palak J / Hirschfield, Gideon M

    Liver international : official journal of the International Association for the Study of the Liver

    2020  Volume 41, Issue 3, Page(s) 535–544

    Abstract: Background and aims: A variety of auto-antibody assays are available as part of the clinical care of patients with liver disease. We sought to better understand the clinical utility of immune serological testing in patients with primary biliary ... ...

    Abstract Background and aims: A variety of auto-antibody assays are available as part of the clinical care of patients with liver disease. We sought to better understand the clinical utility of immune serological testing in patients with primary biliary cholangitis (PBC).
    Methods: We retrospectively analysed data from 2846 patients investigated for liver disease at a UK liver centre between 2001 and 2017. A total of 499 patients with PBC were identified. Immune serology results were examined for their diagnostic utility and prognostic significance to predict transplant-free survival.
    Results: Antimitochondrial antibodies (AMAs) were specific (94.5%) and sensitive (85.6%) for PBC; antinuclear antibodies (ANAs) against glycoprotein 210 (gp210) and sp100 were specific (>98%) but not sensitive (<25%). The disease-specific ANAs were detectable in 29.6% of AMA-negative patients. Anti-gp210 auto-antibodies were significantly associated with elevated serum aminotransferase activity, bilirubin and liver stiffness at presentation (P < .010). Anti-gp210 auto-antibodies predicted non-response to ursodeoxycholic acid (UDCA) by GLOBE criteria (39.3% vs 16.7%, P = .005). Moreover, anti-gp210 was independently associated with death or liver transplantation (HR 3.22, 95% CI 1.49-6.96; P = .003), after accounting for other significant baseline determinants of outcome. Serologic finding of anti-gp210 antibodies conferred an independent risk of death or transplantation (HR 4.13, 95% CI 1.85-9.22; P = .001) after accounting for treatment response.
    Conclusion: In our single-centre cohort of patients with PBC, the presence of anti-gp210 was associated with an adverse presenting phenotype, predicted treatment non-response and independently predicted reduced transplant-free survival.
    MeSH term(s) Antibodies, Antinuclear ; Autoantibodies ; Glycoproteins ; Humans ; Liver Cirrhosis, Biliary ; Retrospective Studies ; Ursodeoxycholic Acid/therapeutic use
    Chemical Substances Antibodies, Antinuclear ; Autoantibodies ; Glycoproteins ; Ursodeoxycholic Acid (724L30Y2QR)
    Language English
    Publishing date 2020-09-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2102783-3
    ISSN 1478-3231 ; 1478-3223
    ISSN (online) 1478-3231
    ISSN 1478-3223
    DOI 10.1111/liv.14688
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol.

    Than, Nwe Ni / Tomlinson, Claire L / Haldar, Debashis / King, Andrew L / Moore, David / Newsome, Philip N

    Systematic reviews

    2016  Volume 5, Page(s) 100

    Abstract: Background: Chronic liver disease (CLD) is a major health burden worldwide. Liver cirrhosis, a form of CLD is the fifth most common cause of death in the UK. Acute-on-chronic liver failure (ACLF) is the result of an acute insult superimposed on patients ...

    Abstract Background: Chronic liver disease (CLD) is a major health burden worldwide. Liver cirrhosis, a form of CLD is the fifth most common cause of death in the UK. Acute-on-chronic liver failure (ACLF) is the result of an acute insult superimposed on patients with liver cirrhosis as a result of precipitating events such as infection or bleeding. ACLF has a high associated mortality as a result of multi-organ failure. The only effective treatment for CLD is liver transplantation, but the treatment is limited by shortage of donor organs. As a result, alternative treatments such as cell therapies have been studied in patients with liver diseases. This study will systematically review the evidence on clinical effectiveness of cell therapies in patients.
    Methods: All types of study design that investigate the effectiveness of cell therapies (haematopoietic, mesenchymal and unsorted cell types) of autologous or allogeneic origin and/or the use of granulocyte colony-stimulating factor in patients with CLD including ACLF will be included (except case reports). Both autologous and allogenic cell types will be included. The primary outcomes of interest are survival, model for end-stage liver disease score, quality of life and adverse events. Secondary outcomes include liver function tests, Child-Pugh score and events of liver decompensation. A literature search will be conducted in the following databases: MEDLINE, MEDLINE in Process, EMBASE and Cochrane Library (CENTRAL, CDSR, DARE, HTA databases). Trial registers will be searched for ongoing trials, as will conference proceedings. Reference lists of relevant articles and systematic reviews will be screened. Randomised controlled trial (RCT) evidence is likely to be scant; therefore, controlled trials and concurrently controlled observational studies will be primarily analysed and uncontrolled observational studies will be analysed where primary outcomes are not reported in the control studies or where uncontrolled studies have longer follow-up. Initial screening of studies will be carried by one reviewer with a proportion checked by another reviewer. Full-text selection will be performed by two reviewers independently against the pre-defined selection criteria. The data collection and the risk of bias assessment will be completed by one reviewer and counter checked by another reviewer for all selected studies. Where appropriate, data will be meta-analysed for each study design, therapy and outcome. Data specifically on ACLF will be treated as a subgroup.
    Discussion: This systematic review will identify the available evidence on the effectiveness of cell therapies in patients with CLD and in ACLF subgroup. The findings will aid decision-making by clinicians and health service leaders.
    Systematic review registration: PROSPERO CRD42016016104.
    MeSH term(s) Acute-On-Chronic Liver Failure/therapy ; Cell- and Tissue-Based Therapy/methods ; Chronic Disease ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Liver Cirrhosis/therapy ; Liver Diseases/therapy ; Mesenchymal Stem Cell Transplantation/methods ; Systematic Reviews as Topic ; Transplantation, Autologous ; Transplantation, Homologous ; Treatment Outcome
    Language English
    Publishing date 2016-06-14
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2662257-9
    ISSN 2046-4053 ; 2046-4053
    ISSN (online) 2046-4053
    ISSN 2046-4053
    DOI 10.1186/s13643-016-0277-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure

    Abhishek Chauhan / Lozan Sheriff / Mohammed T. Hussain / Gwilym J. Webb / Daniel A. Patten / Emma L. Shepherd / Robert Shaw / Christopher J. Weston / Debashis Haldar / Samuel Bourke / Rajan Bhandari / Stephanie Watson / David H. Adams / Steve P. Watson / Patricia F. Lalor

    Nature Communications, Vol 11, Iss 1, Pp 1-

    2020  Volume 12

    Abstract: The molecular mechanisms that drive irreversible acute liver failure remain poorly characterized. Here, the authors show that the recently discovered platelet receptor CLEC-2 (C-type lectin-like receptor) perpetuates and worsens liver damage during acute ...

    Abstract The molecular mechanisms that drive irreversible acute liver failure remain poorly characterized. Here, the authors show that the recently discovered platelet receptor CLEC-2 (C-type lectin-like receptor) perpetuates and worsens liver damage during acute liver injury by blocking restorative neutrophil driven inflammation.
    Keywords Science ; Q
    Language English
    Publishing date 2020-04-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure

    Abhishek Chauhan / Lozan Sheriff / Mohammed T. Hussain / Gwilym J. Webb / Daniel A. Patten / Emma L. Shepherd / Robert Shaw / Christopher J. Weston / Debashis Haldar / Samuel Bourke / Rajan Bhandari / Stephanie Watson / David H. Adams / Steve P. Watson / Patricia F. Lalor

    Nature Communications, Vol 11, Iss 1, Pp 1-

    2020  Volume 12

    Abstract: The molecular mechanisms that drive irreversible acute liver failure remain poorly characterized. Here, the authors show that the recently discovered platelet receptor CLEC-2 (C-type lectin-like receptor) perpetuates and worsens liver damage during acute ...

    Abstract The molecular mechanisms that drive irreversible acute liver failure remain poorly characterized. Here, the authors show that the recently discovered platelet receptor CLEC-2 (C-type lectin-like receptor) perpetuates and worsens liver damage during acute liver injury by blocking restorative neutrophil driven inflammation.
    Keywords Science ; Q
    Language English
    Publishing date 2020-04-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top